Media Briefing

Saturday, April 16th 10:00 am – Media briefing begins Announcement of poster winners and a short presentation

from some of the winning authorsIntroduction of Yehuda Handelsman, MD, FACP, FACE, FNLA

as the new President of AACE

10:25 am – Floor opens to questions from the media 10:30 am – Media Briefing adjourns

OMENTECTOMY ADDED TO ROUX-EN-Y GASTRIC BYPASS OMENTECTOMY ADDED TO ROUX-EN-Y GASTRIC BYPASS IMPROVES GLUCOSE AND ADIPOKINES AT 90 DAYS:IMPROVES GLUCOSE AND ADIPOKINES AT 90 DAYS:

A RANDOMIZED, CONTROLLED TRIALA RANDOMIZED, CONTROLLED TRIAL

TH Dillard1, JQ Purnell1, MD Smith2, J Laut2, W Raum2, D Hong3, E Patterson2

1.Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition. Oregon Health & Science University, Portland, OR2.Department of Surgery, Legacy Good Samaritan Hospital, Portland, OR; 3.Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada

AACE 2011AACE 2011

Coagulation abnormalities in Diabetes Mellitus type 2 and microvascular complications

Ritu Madan MD

Study design

Single center case control study between 2006-2008

60 patients with diabetes, 20 with and 40 without complications (nephropathy, retinopathy, neuropathy)

Equal number of males and females

Evaluation of major coagulation parameters

RESULTS

Results (contd.)

DM DM WITH COMPLICATIONS

P-value Significance

Platelet Count 1.93±0.60 2.06±0.62 0.43 NSPT 14.1±0.91 13.17±1.02 0.5 NSPTT 34.5±0.76 34.6±1.02 0.64 NSFibrinogen 239.5±36.7 259.37±40.85 0.07 NSAT III 95.8±14.71 95.82±10.89 0.99 NSProtein C 101.85±16.4 99.11±23.77 0.68 NSProtein S 63.05±16.85 51.59±10.7 0.002 SPAI-1 37.15±15.18 48.65±22.9 0.04 SvWF 123.19±29.63 155.57±34.61 0.007 SFactor V 98.65±3.43 98.7±4.39 0.9 NSFactor VIII 97.37±5.90 97.98±3.9 0.6 NSFactor IX 98.9±3.64 99.4±1.58 0.3 NS

Conclusions

Microvascular complications of Type-2 Diabetes are associated with changes in coagulation parameters.

Differences in coagulation parameters were seen in diabetics with complications of nephropathy and retinopathy compared to diabetics without these complications.

The magnitude of the coagulation abnormalities is unlikely to cause symptomatic thrombotic events and hence may be clinically silent.